Search clinical trials for: Fluzone® High-Dose (60 µg/strain)

Total 201 results

Medicago

Completed

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Influenza
University of Minnesota

Recruiting

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Solid Organ Transplant

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

Influenza

United States
Sanofi

Terminated

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

Influenza

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Mount Sinai Hospital, Canada

Completed

A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV

Influenza

Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Influenza

United States, Puerto Rico, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Yale University

Completed

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients (SHIVERING)

Influenza | Gammopathy

United States
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
Bassett Healthcare
New York State Department of Health

Completed

Duration of Immune Response to Influenza Vaccination in Patients With RA

Rheumatoid Arthritis

United States
University of Miami

Recruiting

Tfh Dysfunction in HIV and Aging

Human Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Vanderbilt University
Centers for Disease Control and Prevention

Completed

Cell Mediated Immunity in Older Adults (CMI)

Immunity to Influenza Vaccine

United States
Centers for Disease Control and Prevention
Kaiser Permanente; Baylor Scott and White Health; Abt Associates

Completed

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Influenza

United States
Duke University
Boston Medical Center; Centers for Disease Control and Prevention; Children's...

Completed

FLUAD® vs. Fluzone® High-Dose Study

Quality of Life | Pain | Adverse Drug Event | Injection Site Reaction | Side Effect of Drug

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
St. Jude Children's Research Hospital

Completed

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

Cancer | HIV

United States
University of Colorado, Denver
Colorado Clinical & Translational Sciences Institute

Completed

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

Rheumatologic Disorder | Dialysis | Human Immunodeficiency Virus (HIV) | Solid Organ Transplant Recipient (Liver, Kidney, Heart) | Bone Marrow Transplant (BMT)

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013

Influenza
Suping Wang
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults (HIV)

Hepatitis B Vaccine
Suping Wang
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients

Hepatitis B Vaccine
Saad Jamshed MD
Sanofi

Completed

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy (IMMUNE)

Cancer | Influenza Viral Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
Shanxi Medical University
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination Among Drug Users

Hepatitis B Vaccination
National Institute of Allergy and Infectious Diseases...

Completed

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Healthy Volunteer

United States
Medicago

Completed

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
University of Alabama at Birmingham

Recruiting

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Taiwan
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
Insight Therapeutics, LLC
Brown University

Completed

High Dose Influenza Vaccine in Nursing Home - Pilot Study

Influenza

United States
Centre Hospitalier Universitaire de Nice

Recruiting

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX (CHRONOVAX)

Vaccination; Infection

France
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan
Inova Health Care Services

Completed

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

Influenza, Human | Transplantation Infection

United States
Yale University

Completed

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2)

Multiple Myeloma | Influenza | Waldenstrom's Macroglobulinemia | MGUS | Plasma Cell Disorders

United States
Duke University
Johns Hopkins University; Centers for Disease Control and Prevention

Completed

Simultaneous RZV and aIIV4 Vaccination

Quality of Life | Pain | Adverse Drug Event | Injection Site Reaction

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

Influenza | Flu

United States

Search clinical trials for: Fluzone® High-Dose (60 µg/strain)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations